20 results about "Basal cell" patented technology

The invention relates to the technical field of biological medicine, provides novel application of IL-17a, and particularly relates to application of an IL-17a inhibitor in preparation of a medicine for treating age-related olfactory dysfunction. The research result shows that the expression increase of the IL-17a can trigger an inflammation signal and damage the olfactory function. Administration of the IL-17a inhibitor Y-320 or a neutralizing antibody promotes sensory neuron regeneration in the olfactory epithelium (OE) and reverses age-related respiratory metaplasia. In addition, conditional knockout of IL-17a in T cells can promote olfactory epithelium regeneration by promoting recruitment and differentiation of horizontal basal cells (HBCs) into globular basal cells (GBCs). In general, the research of the invention determines the previously undetermined effect of the IL-17a in olfactory epithelium regeneration and age-related olfactory function defects, and provides evidence for the IL-17a as a potential therapeutic target for olfaction of the elderly.

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, and a selective organ targeting lipid. The lipid composition can further comprise a phospholipid. Further described herein are high-potency intravenous dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

The invention belongs to the cross technical field of biomedical detection and information technology, and particularly relates to a detection kit, system and method for cancer immunotherapy curative effect prediction. The detection kit comprises a combination of a first detection reagent for specifically detecting the LAMC2 gene or protein and a second detection reagent for specifically detecting the SPP1 gene or protein. Research finds that in a complex tumor microenvironment, LAMC < 2 + > basal cells and SPP1 < + > macrophages, which are respectively derived from specific subgroups of tumor cells and immune cells, jointly form a key biological signal capable of remarkably influencing immunotherapy response according to the existence and the quantity of the two specific subgroups of the LAMC < 2 + > basal cells and the SPP1 < + > macrophages. By jointly detecting the pair of biomarkers with a synergistic effect, the problems of insufficient prediction accuracy and incapability of reflecting tumor microenvironment heterogeneity caused by dependence on PD-L1, TMB and other single markers in the prior art are solved, and the technical effect of remarkably improving the sensitivity and reliability of immunotherapy curative effect prediction is achieved.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

This invention discloses the application of SNCG protein in the auxiliary diagnosis of prostate cancer, belonging to the field of biomedical technology. The application involves using reagents specifically designed to detect SNCG protein expression in biological samples to prepare products for the auxiliary diagnosis of prostate cancer. Through proteomic analysis of urinary proteins from prostate cancer patients and normal men, this invention revealed that the concentration of SNCG protein in the urine of prostate cancer patients was significantly higher than that in the normal male group. Immunohistochemical analysis of paraffin-embedded tissue samples from prostate cancer patients and surrounding normal prostate tissue showed that SNCG protein has a certain expression rate in prostate cancer, and that SNCG protein is also expressed in the basal cells of normal prostate glands, indicating a certain relationship between SNCG protein and the occurrence and development of prostate cancer. This invention can be used to assist in the diagnosis of prostate cancer and difficult cases, thereby improving the diagnosis rate and survival rate of patients.

The invention discloses a skin cell nucleus nutritional agent containing traditional Chinese medicine components and capable of improving ichthyosis and a preparation method, and relates to the technical field of preparation of skin cell nucleus nutritional agents. Comprising the following raw materials: modified vitamin A propionate, a traditional Chinese medicine extract, modified hydrogenated lecithin, squalane, beewax, stearyl alcohol, vaseline, glycerin, sodium hyaluronate, beta-glucan, propylene glycol, potassium cetyl phosphate, a preservative, allantoin, deionized water, triethanolamine and a lipid solvent. According to the invention, the modified tretinoin propionate is added, and the modified tretinoin propionate is subjected to double-grafting modification through glycyrrhetinic acid-hyaluronic acid oligosaccharide and is gently combined with a basal cell tretinoin receptor in a targeted manner, so that excessive proliferation of basal cells can be inhibited, and normal differentiation of keratinocytes can be promoted; wherein the glycyrrhetinic acid component can resist inflammation, relieve and reduce self-irritation, and the hyaluronic acid oligosaccharide can improve targeting and transdermal efficiency, avoid light / oxygen degradation and provide a core regulation effect for restoring the 28-day metabolic cycle of basal cells.

The present invention relates to a method for producing respiratory organoids by proliferating and differentiating respiratory epithelial cells. [Solution] Unlike conventional respiratory organoids in which epithelial cells present at the apical end of the respiratory tract develop inside the organoid, the respiratory organoid of the present invention has a morphology in which the ciliated structure, which is made up of epithelial cells, is located in the outer layer of the organoid, secretory cells are located inside, and stem cell-like basal cells present at the base of the respiratory tissue are also located inside the organoid. This morphology is similar to that of actual respiratory tissue and has been observed to exhibit normal functions of epithelial cells, such as the motility of ciliated cells. Therefore, by manufacturing organoids using the manufacturing method of the present invention, it is possible to manufacture respiratory organoids that can accurately mimic actual tissue.

The invention discloses a lung tissue organoid culture method. The method comprises the following steps: firstly, carrying out three-dimensional differentiation culture on matrigel by utilizing lung basal cells in vitro to construct an organoid with alveolar epithelium characteristics; then, the organ is transplanted into the spleen of a recipient animal subjected to ectopic surgery (shifted to subcutaneous tissues). The rich blood vessel network and the unique microenvironment of the spleen greatly promote rapid vascularization, structural remodeling and functional maturation of organoids, and lung tissue highly simulating natural alveolus is formed. The invention overcomes the defects of insufficient vascularization and immature function of the existing organ-like model, provides an excellent in-vivo platform for researching lung development and disease mechanisms and carrying out drug screening and toxicological evaluation, and has important application value in the field of regenerative medicine.

Provided herein are ex vivo methods of engineering or culturing a submucosal gland (SMG) organoid, comprising isolating submucosal gland basal cells and / or myoepithelial cells (e.g., human cells), and / or submucosal gland stem and / or progenitor cells (e.g., human cells), and culturing such cells with an agonist or ligand of ERBB (e.g., in a three- dimensional matrix). Also provided herein are SMG organoid engineered or cultured ex vivo. Also provided herein are methods of identifying an agent that reduces airway mucus production using an ex vivo SMG organoid described herein. Also provided herein is a method of treating a hypersecretory airway disorder or disease, or a disorder associated with an increased secretion from submucosal glands, in a subject, comprising administering to the subject an agent that inhibits ERBB.

Described herein are compositions and methods for potent and long-lasting gene editing in a cell. The gene editing may result in an increase in function of a gene product. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. The presently disclosed compositions comprise a lipid composition, which can comprise an ionizable cationic lipid, a sterol, a phospholipid, and a selective organ targeting lipid. Also described herein are methods for treating a disease or disorder, such as a lung disease or disorder, involving the presently disclosed compositions.

The present disclosure relates to methods of differentiating pluripotent stem cells or lung progenitor cells into epithelial or basal cells. The present disclosure also relates to epithelial or basal cells made by such methods, organoids containing such epithelial or basal cells, and methods of using the same. The present disclosure also relates to differentiation media for use in the same.

The present invention relates to an antibody or an antigen-binding fragment thereof that binds to a basal cell adhesion molecule (BCAM), an antibody-drug conjugate comprising the antibody or the antigen-binding fragment thereof, a nucleic acid encoding a nucleotide of the antibody or the antigen-binding fragment thereof, and an antibody-drug conjugate comprising the antibody or the antigen-binding fragment thereof. And a method for obtaining the antibody or the antigen-binding fragment and the antibody-drug conjugate thereof. The invention also relates to the use of said antibodies or antigen-binding fragments thereof and antibody-drug conjugates for the prevention, amelioration or treatment of diseases associated with BCAM function or expression, such as cancer.

The present disclosure relates to anti-basal cell adhesion molecule (BCAM) antibody-drug conjugates in which the anti-BCAM antibody is conjugated to an anti-tumor compound via a linker, pharmaceutical compositions comprising the anti-BCAM antibody-drug conjugates, and methods of treating cancer by administering an effective amount of the anti-BCAM antibody-drug conjugate to a subject in need thereof.

The invention relates to a preservation and separation method of airway basal cells, and belongs to the technical field of biology. Comprising the following steps: S1, airway tissue cleaning preparation; s2, airway tissue cleaning; s3, carrying out digestive enzyme digestion on the airway tissues; s4, airway tissue basal cells are inoculated and cultured; and S5, detecting the quantity and form of the airway tissue basal cells. According to the invention, antibiotics special for respiratory tract microfungal infection, an anti-apoptosis and anti-inflammatory reagent and a reagent for improving microcirculation are creatively adopted as the preserving fluid, so that the cell stress resistance in tissues is improved, the viability of basal cells is greatly improved, besides, through the organoid enzymatic hydrolysate in the composite enzymatic hydrolysate, the enzymolysis is thorough, the enzymolysis time is greatly shortened, and the preservation time is shortened. The method has the advantages that the operation steps are simple, the cell acquisition rate is high, the quantity of the extracted cells is enough, and the cell viability is high.

The application discloses a biomarker of epithelial ovarian cancer and application thereof. The biomarker comprises a basal cell adhesion molecule, a mesothelin and a folate receptor alpha, or coding nucleic acids of the basal cell adhesion molecule, the mesothelin and the folate receptor alpha, wherein the coding nucleic acids comprise mRNA or cDNA. An EOC CTC RNA diagnosis model is constructed by taking the biomarker as a feature, the sensitivity and the specificity of which can reach 88% and 83% respectively, and the model can dynamically monitor the progress of a patient's disease, and the patient's recurrence can be found earlier than by using imaging and existing serum indexes.

This therapeutic or prophylactic agent is for at least one disease selected from the group consisting of fibrotic diseases, inflammatory diseases, and geriatric diseases, and contains extracellular vesicles derived from basal cells as an active ingredient.

The invention discloses a plant composition for promoting cutin renewal and smoothing skin and application of the plant composition, and belongs to the technical field of cosmetics. The composition is prepared from a pomegranate fruit extract, a kale leaf extract, a dendrobium officinale stem extract and phytosterol according to a specific ratio, wherein the dendrobium officinale stem extract is obtained by combining a choline chloride-oxalic acid eutectic solvent with microjet extraction; in the composition, the pomegranate fruit extract promotes keratinocyte regeneration, the kale leaf extract accelerates old and waste cutin to fall off, and the pomegranate fruit extract and the kale leaf extract cooperate to regulate cutin metabolism; the dendrobium officinale stem extract enhances the skin moisturizing capacity, softens cutin and creates a moist renewal environment; phytosterol can repair the skin barrier and improve the basal layer cell viability. The four components form a complete action chain of deep activation, metabolism regulation and barrier repair, endogenously promote cutin renewal, have the effects of exfoliating, skin smoothing, long-acting moisturizing and barrier repair, are mild and non-irritant, and are suitable for people with sensitive skin.

This invention relates to the field of pathogen infection detection technology, specifically a method for visually tracking human bronchial organoids infected with Mycoplasma pneumoniae. It includes the following steps: (1) Constructing human bronchial organoids: culturing mature human bronchial organoids with cavities, the organoids comprising ciliated cells, basal cells, goblet cells, and Club cells, having a polarized three-dimensional structure with the apex facing outwards; (2) Mycoplasma pneumoniae culture and fluorescent labeling: Mycoplasma pneumoniae is amplified and cultured in MP complete medium, and then fluorescently labeled using CellTrace far-infrared cell staining solution; (3) Co-culture for infection: Mycoplasma pneumoniae fluorescently labeled in step (2) is co-cultured with the human bronchial organoids from step (1) for infection; (4) Live cell dynamic fluorescence tracking: Non-invasive in situ continuous imaging is performed on the human bronchial organoids infected by MP in step (3). This invention can achieve non-invasive dynamic tracking of the entire process of MP infection.

The invention discloses an airway basal cell-N-acetylcysteine conjugate, which is prepared by the following steps: adding DMPE-PEG-maleimide and N-acetylcysteine into a solution, incubating at room temperature, and centrifuging, so as to obtain a DMPE-PEG-maleimide-N-acetylcysteine compound; and adding the DMPE-PEG-maleimde-N-acetylcysteine compound into a cell suspension of human airway basal cells, and incubating at room temperature to obtain the human airway basal cell suspension. According to the invention, DMPE-PEG-maleimide is used as a non-invasive carrier, and airway basal cells and a drug-N-acetylcysteine are coupled; during treatment, inflammatory response can be controlled while lung injury is effectively repaired, cells can play a homing role, and the medicine is carried to reside at the injured part for long-acting treatment. The research of the invention is of great significance to the treatment of pneumonia.

Described herein are compositions and methods for potent and long-lasting gene editing in a cell. The gene editing may result in an increase in function of a gene product. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. The presently disclosed compositions comprise a lipid composition, which can comprise an ionizable cationic lipid, a sterol, a phospholipid, and a selective organ targeting lipid. Also described herein are methods for treating a disease or disorder, such as a lung disease or disorder, involving the presently disclosed compositions.